Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
European Radiology
Erschienen in: European Radiology 11/2006

01.11.2006 | Breast

Monitoring therapeutic efficacy in breast carcinomas

verfasst von: Anne A. Tardivon, Liliane Ollivier, Carl El Khoury, Fabienne Thibault

Erschienen in: European Radiology | Ausgabe 11/2006

Einloggen, um Zugang zu erhalten

Abstract

The aim of imaging during and after neoadjuvant therapy is to document and quantify tumor response: has the tumor size been accurately measured? Certainly, the most exciting information for the oncologists is: can we identify good or nonresponders, and can we predict the pathological response early after the initiation of treatment? This review article will discuss the role and the performance of the different imaging modalities (mammography, ultrasound, magnetic resonance imaging and FDG-PET imaging) for evaluating this therapeutic response. It is important to emphasize that, at this time, clinical examination and conventional imaging (mammography and ultrasound) are the only methods recognized by the international criteria. Magnetic resonance imaging and FDG-PET imaging are very promising for predicting the response early after the initiation of neoadjuvant chemotherapy.
Literatur
1.
Bonadonna G, Vlagussa P, Brmabilla C et al (1998) Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 16:93–100PubMed
2.
van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L (2001) Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19:4224–4237PubMed
3.
Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 96–102
4.
Newman LA, Buzdar AU, Singletary SE et al (2002) A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conserving therapy feasibility. Ann Surg Oncol 9:228–234CrossRefPubMed
5.
Fischer U, Kopka L, Grabbe E (1999) Breast carcinoma: effect of preoperative contrast-enhanced MR imaging on the therapeutic approach. Radiology 213:881–888PubMed
6.
Esserman L, Hylton N, Yassa L, Barclay J, Frankel S, Sickles E (1999) Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. J Clin Oncol 17(1):110PubMed
7.
Tillman BGF, Orel SG, Schnall MD, Schultz DJ, Tan JE, Solin LJ (2002) Effect of breast magnetic resonance imaging with early-stage breast carcinoma. J Clin Oncol 20(16):3413–3423CrossRefPubMed
8.
Bedrosian I, Mick R, Orel SG et al (2003) Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging. Cancer 98:468–473CrossRefPubMed
9.
Sardanelli F, Giuseppetti GM, Panizza P et al (2004) Sensitivity of MRI versus mammography for detecting foci of multifocal, multicentric breast cancer in fatty and dense breasts using the whole-breast pathologic examination as a gold standard. Am J Roentgenol 183:1149–1157
10.
Berg WA, Gutierrez L, Ness Aiver MS et al (2004) Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology 233:830–849PubMed
11.
Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216CrossRefPubMed
12.
Ollivier L, Vanel D, Leclère J (2002) Monitoring tumour response. Cancer Imaging 3:5–6
13.
Helvie MA, Joynt LK, Cody RL et al (1996) Locally advanced breast carcinoma : accuracy of mammography vs clinical examination in the prediction of residual disease after chemotherapy. Radiology 198:327–332PubMed
14.
Vinnicombe SJ, MacVicar AD, Guy RL et al (1996) Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation. Radiology 198:333–340PubMed
15.
Moskovic EC, Mansi JL, King DM et al (1993) Mammography in the assessment of response to medical treatment of large primary breast cancer. Clin Radiol 47:339–344CrossRefPubMed
16.
Huber S, Wagner M, Zuna I et al (2000) Locally advanced breast carcinoma: evaluation of mammography in the prediction of residual disease after induction chemotherapy. Anticancer Res 20:553–558PubMed
17.
Balu-Maestro C, Chapellier C, Bleuse A et al (2002) Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits in MRI. Breast Cancer Res Treat 72:145–152CrossRefPubMed
18.
Fornage BD, Toubas O, Morel M (1987) Clinical, mammographic and sonographic determination of preoperative breast cancer size. Cancer 60:765–771PubMedCrossRef
19.
Herrada J, Iyer RB, Atkinson EN et al (1997) Relative value of physical examination, mammography, and breast sonography in evaluating the size of primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. Clin Cancer Res 3:1565–1569PubMed
20.
Schott ZF, Roubidoux MA, Helvie MA et al (2005) Clinical and radiological assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat 92:231–238CrossRefPubMed
21.
Roubidoux MA, Le Carpentier GL, Fowles JB et al (2005) Sonographic evaluation of early-stage breast cancers that undergo neoadjuvant chemotherapy. J Ultrasound Med 24:885–895PubMed
22.
Walsh R, Kornguth PJ, Soo MS, Bentley R, Delong DM (1997) Axillary lymph nodes; mammographic, pathologic and clinical correlation. AJR 168:33–38PubMed
23.
Feu J, Tresserra F, Fabregas R et al (1997) Metastatic breast carcinoma in axillary lymph nodes: in vitro US detection. Radiology 205:831–835PubMed
24.
Tschammler A, Ott G, Schang T, Seelbach-Goebel B, Schwager K, Hahn D (1998) Lymphadenopathy : differentiation of benign from malignant disease - color Doppler US assessment of intranodal angioarchitecture. Radiology 208:117–123PubMed
25.
Yang WT, Chang J, Metreweli C (2000) Patients with breast cancer : differences in color Doppler flow and gray-scale US features of benign and malignant axillary lymph nodes. Radiology 215:568–573PubMed
26.
Lernevall A (2000) Imaging of axillary lymph nodes. Act Oncol 39(3):277–281CrossRef
27.
Balu-Maestro C, Cazenave F, Marcy PY, Tran C (1996) Evaluation de la réponse tumorale à la chimiothérapie par l’IRM et l’écho Doppler couleur. J Le Sein 3:194–202
28.
Huber S, Medl M, Helblich T et al (2000) Locally advanced breast carcinoma: computer assisted semiquantitative analysis of color Doppler ultrasonography in the evaluation of tumor response to neoadjuvant chemotherapy (work in progress). J Ultrasound Med 19:601–607PubMed
29.
Singh S, Pradhan S, Shukla RC, Ansari MA, Kumar A (2005) Color Doppler ultrasound as an objective assessment tool for chemotherapeutic response in advanced breast cancer. Breast Cancer 12:45–51CrossRefPubMed
30.
Huber S, Helblich T, Kettenbach J, Dock W, Zuna I, Delorme S (1998) Effects of a microbubble agent on breast tumors: computer-assisted quantitative assessment with color Doppler US - Early experience. Radiology 208:485–489PubMed
31.
Vallone P, D’Angelo R, Filice S et al (2005) Color-Doppler using contrast medium in evaluating the response to neoadjuvant treatment in patients with locally advanced breast carcinoma. Anticancer Res 25:595–599PubMed
32.
33.
34.
Partbridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM (2002) Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. Am J Roentgenol 179:1193–1199
35.
Rosen EL, Blackwell KL, Baker JA et al (2003) Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. Am J Roentgenol 181:1275–1282
36.
Thibault F, Nos C, Meunier M et al (2004) MRI for surgical planning in patients with breast cancer who undergo preoperative chemotherapy. Am J Roentgenol 183:1159–1168
37.
Londero V, Bazzocchi M, Del Frate C et al (2004) Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol 14:1371–1379CrossRefPubMed
38.
Newman LA, Buzdar AU, Singletary SE et al (2002) A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility. Ann Surg Oncol 9:228–234CrossRefPubMed
39.
Rieber A, Brambs HJ, Gabelmann A, Heilmann V, Kreienberg R, Kuhn T (2002) Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur Radiol 7:1711–1719
40.
Warren RML, Bobrow LG, Earl HM et al (2004) Can breast MRI help in the management of women with breast cancer treated by neoadjuvant chemotherapy? Br J Cancer 90:1349–1360CrossRefPubMed
41.
Martincich L, Montemurro F, De Rosa G et al (2004) Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat 67–76
42.
Cheung YC, Chen SC, Su MY et al (2003) Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI. Breast Cancer Res Treat 78:51–58CrossRefPubMed
43.
Partbridge SC, Gibbs JE, Lu Y et al (2005) MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. Am J Roentgenol 184:1774–1781
44.
Gilles R, Guinebretière JM, Toussaint C et al (1994) Locally advanced breast cancer: contrast-enhanced subtraction MR imaging of response to preoperative chemotherapy. Radiology 191:633–638PubMed
45.
46.
Rieber A, Zeitler H, Rosenthal H et al (1997) MRI of breast cancer: influence of chemotherapy on sensitivity. Br J Radiol 70:452–458PubMed
47.
Wasser K, Klein SK, Fink C et al (2003) Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution. Eur Radiol 13:80–87PubMed
48.
Delille JP, Slanetz PJ, Yeh ED et al (2003) Invasive ductal breast carcinoma response to neoadjuvant chemotherapy: non-invasive monitoring with functional MR imaging - pilot study. Radiology 228:63–69PubMed
49.
El Khoury C, Servois V, Thibault F et al (2005) MR quantification of the washout changes in breast tumors under preoperative chemotherapy: feasibility and preliminary results. Am J Roentgenol 184:1499–1504
50.
51.
Daldrup-Link HE, Brasch RC (2003) Macromolecular contrast agents for MR mammography: current status. Eur Radiol 13:354–365PubMed
52.
Preda A, van Vliet M, Krestin GP, Brasch RC, van Dijke CF (2006) Magnetic resonance macromolecular agents for monitoring microvessels and angiogenesis inhibition. Inv Radiol 41:325–331CrossRef
53.
Roebuck JR, Cecil KM, Schnall MD, Lenkinski RE (1998) Human breast lesions: characterization with proton MR spectroscopy. Radiology 209:269–275PubMed
54.
Kvistad KA, Bakken IJ, Gribbestad IS et al (1999) Characterization of neoplastic and normal human breast tissues with in vivo (1) H MR spectroscopy. J Magn Reson Imaging 10:159–164CrossRefPubMed
55.
Yeung DK, Yang WT, Tse GM (2002) Human breast cancer: in vivo proton MR spectroscopy in the characterization of histopathological subtypes and preliminary observations in axillary node metastases. Radiology 225:190–197PubMed
56.
Cecil KM, Schnall MD, Siegelman ES, Lenkinski RE (2001) The evaluation of human breast lesions with magnetic resonance imaging and proton magnetic resonance spectroscopy. Breast Cancer Res Treat 68:45–54CrossRefPubMed
57.
Tse GMK, Humairah Cheung S, Pang LM et al (2003) Characterization of lesions of the breast with proton MR spectroscopy: comparison of carcinomas, benign lesions, and phyllodes tumors. Am J Roentgenol 181:1267–1272
58.
Jagannathan NR, Kumar M, Seenu V et al (2001) Evaluation of total choline from in vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer 84:1016–1022CrossRefPubMed
59.
Meisamy S, Bolan PJ, Baker EH et al (2004) Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1) H MR spectroscopy-a pilot study at 4 T. Radiology 233:424–431PubMed
60.
Quon A, Gambhir SS (2005) FDG-PET and beyond : molecular cancer imaging. J Xlin Oncol 23:1664–1673CrossRef
61.
Schelling M, Avril N, Nahrig J et al (2000) Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18:1689–1695PubMed
62.
Bassa P, Kim EE, Inoue T et al (1996) Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 37:931–938PubMed
63.
Gennari A, Donati S, Salvadori B et al (2000) Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. Clin Breast Cancer 1:156–161PubMedCrossRef
64.
Jansson T, Westlin JE, Ahlstrom H et al (1995) Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer. A method for early therapy evaluation? J Clin Oncol 13:1470–1477PubMed
65.
Mankoff DA, Dunnwald LK, Gralow JR et al (2002) Blood flow and metabolism in locally advanced breast cancer: Relationship to response to therapy. J Nucl Med 43:500–509PubMed
66.
Smith IC, Welch AE, Hutcheon AW et al (2000) Positron emission tomography using [18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18:1676–1688PubMed
67.
Stafford SE, Gralow JR, Schubert EK et al (2002) Use of serial FDG PET to measure the response of bone-dominated breast cancer to therapy. Acad Radiol 9:913–921CrossRefPubMed
68.
Tiling R, Linke R, Untch M et al (2001) 18F-FDG PET and 99mTc-sestamibi scintiomammography for monitoring breast cancer response to neoadjuvant chemotherapy: a comparative study. Eur J Nucl Med 28:711–720CrossRefPubMed
69.
Dehdashti F, Flanagan FL, Mortimer JE et al (1999) Positron emission tomographic assessment of “metabolic flare” to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 26:51–56CrossRefPubMed
70.
Mortimer JE, Dehdashti F, Siegel BA et al (2001) Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 19:2797–2803PubMed
71.
Ciernik IF, Dizendorf E, Baumert BG et al (2003) Radiation treatment planning with an integrated positron emssion and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 57:853–863CrossRefPubMed
72.
Giraud P, Grahek D, Montravers F et al (2001) (18)F-deoxyglucose (FDG) image fusion for optimization of conformal radiotherapy of lung cancers. Int J Radiat Oncol Biol Phys 49:1249–1257CrossRefPubMed
73.
Kelloff GJ, Krohn KA, Larson SM et al (2005) The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res 11:7967–7985CrossRefPubMed
Metadaten
Titel
Monitoring therapeutic efficacy in breast carcinomas
verfasst von
Anne A. Tardivon
Liliane Ollivier
Carl El Khoury
Fabienne Thibault
Publikationsdatum
01.11.2006
Verlag
Springer-Verlag
Erschienen in
European Radiology / Ausgabe 11/2006
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-006-0317-z

Weitere Artikel der Ausgabe 11/2006

European Radiology 11/2006 Zur Ausgabe

Editorial

Molecular imaging in radiology: the latest fad or the new frontier?

Experimental

Insertion of virtual pulmonary nodules in CT data of the chest: development of a software tool

Cardiac

MR evaluation of pulmonary vein diameter reduction after radiofrequency catheter ablation of atrial fibrillation

Cardiac

Imaging in percutaneous ablation for atrial fibrillation

Interventional

CT-guided interstitial brachytherapy in the local treatment of extrahepatic, extrapulmonary secondary malignancies

Musculoskeletal

Acute knee trauma: role of ultrasound

Neu im Fachgebiet Radiologie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise